Patents Represented by Attorney, Agent or Law Firm James H. Shalek, Esq.
  • Patent number: 6689399
    Abstract: The present invention provides an anti-inflammatory composition for treatment of joint and muscle pain through transdermnal delivery of a capsacinoid in conjunction with glucosamine. The ingredients of the composition of the present invention, namely, a capsacinoid in combination with a primary amine, such as glucosamine, at a high concentration, interact in a synergistic manner to provide a prolonged effect of pain relief when used in the treatment of joint and/or muscle pain associated with an inflammatory response. The prolonged pain relief effect is achieved without incurring the intense burning or stinging sensation usually associated with topical capsaicin administration. The present invention also provides methods for relieving joint and/or muscle pain associated with an inflammatory response, which employ the composition of the present invention.
    Type: Grant
    Filed: March 16, 2000
    Date of Patent: February 10, 2004
    Inventor: James R. Dickson
  • Patent number: 6455662
    Abstract: Curable mixtures suitable for the manufacture of moldings, coatings and foams comprises a) an epoxy resin having more than one 1,2-epoxy group per molecule, b) as curing catalyst, an imidazole compound of formula I wherein R1, R2 and R3 are each independently of the others a hydrogen atom, a halogen atom, alkyl having from 1 to 20 carbon atoms, alkoxy having from 1 to 20 carbon atoms, unsubstituted or halo-, nitro-, C1-4alkyl- or C1-4alkoxy-substituted aralkyl having from 7 to 20 carbon atoms, or unsubstituted or halo-, nitro-, C1-4alkyl- or C1-4alkoxy-substituted aryl having from 6 to 20 carbon atoms, and R4 is alkyl having from 1 to 20 carbon atoms, alkenyl having from 2 to 20 carbon atoms, alkynyl having from 2 to 20 carbon atoms, unsubstituted or halo-, nitro-, C1-4alkyl- or C1-4alkoxy-substituted aralkyl having from 7 to 20 carbon atoms or unsubstituted or halo-, nitro-, C1-4alkyl- or C1-4alkoxy-substituted aryl having from 6 to 20 carbon atoms; and c) curing agent such as dicyadiami
    Type: Grant
    Filed: December 4, 2000
    Date of Patent: September 24, 2002
    Assignee: Vantico Inc.
    Inventor: VĂ©ronique Hall-Goulle
  • Patent number: 6433084
    Abstract: The present invention relates to a powder coating composition containing as binder one or more than one poly(meth)acrylic resin having free carboxyl groups and, as hardener for these poly(meth)acrylic resins, one or more than one epoxy resin having a molecular weight of up to 1500, wherein the epoxy resins comprise at least 70% by weight of glycidyl esters which are selected from the group consisting of aliphatic and cycloaliphatic polyglycidyl polycarboxylates. More particularly, the present invention relates to a coating composition, which is free of carboxyl-functional polyesters, comprising a binder consisting of one or more than one poly(meth)acrylic resin having free carboxyl groups and, as hardener for the poly(meth)acrylic resin, one or more than one epoxy resin having a molecular weight of up to 1500, wherein the epoxy resin is a cycloaliphatic polyglycidyl polycarboxylate or mixtures thereof.
    Type: Grant
    Filed: April 23, 1999
    Date of Patent: August 13, 2002
    Assignee: Vantico Inc.
    Inventor: Philippe-Guilhaume Gottis
  • Patent number: 6271369
    Abstract: Chimeric molecules comprising a virus targeting antisense oligonucleotide moiety attached to an activator of 2-5A-dependent RNase.
    Type: Grant
    Filed: October 14, 1997
    Date of Patent: August 7, 2001
    Assignees: The United States of America as represented by the Department of Health and Human Services, The Cleveland Clinic Foundation
    Inventors: Paul F. Torrence, Robert H. Silverman, Ratan K. Maitra, Krystyna Lesiak
  • Patent number: 6214805
    Abstract: The present invention relates to methods of inhibiting infection by RNA viruses with complexes of an activator of RNase L and an oligonucleotide that is capable of binding to the genome, antigenome or mRNAs of a negative strand RNA virus to specifically cleave the genomic or antigenomic RNA strand of the virus. In accordance with the present invention, the methods and complexes of the invention may be applied to target any negative strand RNA virus. The invention in one embodiment relates to a covalently linked complex of an oligonucleotide that is capable of binding to the genomic or antigenomic template RNA strand of a negative strand RNA virus and/or binding to an mRNA of a viral protein (an “antisense oligonucleotide”) coupled to an activator of RNase L. In a preferred embodiment of the present invention, the oligonucleotide component of the complex is complementary to a region of the viral genomic RNA strand characterized by repeated or consensus sequences.
    Type: Grant
    Filed: November 3, 1997
    Date of Patent: April 10, 2001
    Assignees: The United States of America as represented by the Department of Health and Human Services, The Cleveland Clinic Foundation
    Inventors: Paul F. Torrence, Robert Hugh Silverman, Nick Mario Cirino, Guiying Li, Wei Xiao, Mark R. Player